SPIE Quantum West to Showcase High-Profile Industry Voices
2.2.2021 20:03:00 EET | Business Wire | Press release
SPIE, the international society for optics and photonics, announces the program for its inaugural industry-focused SPIE Quantum West conference 6-11 March. Organized in partnership with the Quantum Economic Development Consortium (QED-C), Quantum West will be held online during the SPIE Photonics West Digital Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005101/en/
Attendance at Quantum West is free to all registered participants of SPIE Photonics West, but registration is required.
The four sessions will provide a wide range of opportunities to learn more about the role of photonics in the development of quantum technology as quantum moves from research and development to engineering products for the commercial marketplace, while building mainstream infrastructures and supply chains. Speakers’ topics include “Quantum Technology as an Enabler,” “Photonics’ Roles in Superconducting Quantum Computing,” and “Building an Industry: Lessons Learned from a Half-Century of Growth in the Photonics Industry.” The four-day event, co-hosted by QED-C Deputy Director Celia Merzbacher and ColdQuanta Executive Chairman and DRS Daylight Solutions Senior Vice President Tim Day, will also include a market report from the Boston Consulting Group.
The international slate of speakers includes Imperial College London’s Peter Knight, who is also a member of the UK’s Quantum Technology Strategic Advisory Board; Andrew Lord, who heads British Telecom’s optical core, access, and quantum research; Google Product Manager Eric Ostby; Toptica’s co-founder and CTO Wilhelm G. Kaenders; Kaitlin R. Moore, a research physicist and principal investigator with SRI International; and Mercedes Gimeno-Segovia, senior director of quantum architecture at PsiQuantum.
A panel discussion on the final day featuring Toptica’s Mark Tolbert, IBM’s Jason Orcutt, Anchored In’s Anke Lohman, and Hamamatsu’s Klea Dhimitri, and moderated by Tim Day, will explore the future of photonics and quantum (“2021 and Beyond”), the challenges of developing a new market, and how photonics will support that.
“We are delighted to partner with the QED-C in launching the first annual Quantum West event,” said SPIE Director of Industry Development Stephen Anderson. “As one of the few industry-oriented quantum technology events to focus on the role of optics and photonics in the emerging market for quantum-enabled devices, Quantum West will play a key role in showcasing the future of the quantum industry and the opportunities it presents for photonics technologies."
“Optics and photonics are critical enabling technologies for many quantum-based applications, including for sensing, communications and computing,” noted QED-C’s Merzbacher. “Quantum West will bring together the photonics and quantum communities to help build the ecosystem and supply chain for the emerging quantum industry.”
To find out more about Quantum West and to register for the event, visit the SPIE Quantum West page.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5.8 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org.
About Quantum Economic Development Consortium:
The Quantum Economic Development Consortium (QED-C) is an industry-driven consortium managed by SRI International and established in response to the 2018 National Quantum Initiative Act. Membership includes more than 120 US companies from across the supply chain and more than 40 academic institutions and other stakeholders. The consortium seeks to enable and grow the quantum industry and associated supply chain. For more about QED-C, visit our website or follow us on Twitter @The_QEDC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005101/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom